Frank Griesinger

14.4k total citations · 1 hit paper
275 papers, 5.1k citations indexed

About

Frank Griesinger is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Frank Griesinger has authored 275 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 167 papers in Pulmonary and Respiratory Medicine, 127 papers in Oncology and 50 papers in Molecular Biology. Recurrent topics in Frank Griesinger's work include Lung Cancer Treatments and Mutations (154 papers), Lung Cancer Research Studies (57 papers) and Lung Cancer Diagnosis and Treatment (47 papers). Frank Griesinger is often cited by papers focused on Lung Cancer Treatments and Mutations (154 papers), Lung Cancer Research Studies (57 papers) and Lung Cancer Diagnosis and Treatment (47 papers). Frank Griesinger collaborates with scholars based in Germany, United States and France. Frank Griesinger's co-authors include Bernhard Wörmann, Wolfgang Hiddemann, Andrea Biondi, Susanne Schnittger, Enrico Gottardi, A Parreira, Paula Gameiro, Giuseppe Saglio, V Rossi and Jacques J. M. van Dongen and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Frank Griesinger

255 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease

1999 865 citations Frank Griesinger et al. profile →

Peers

Countries citing papers authored by Frank Griesinger

Since Specialization

Citations

This map shows the geographic impact of Frank Griesinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Griesinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Griesinger more than expected).

Fields of papers citing papers by Frank Griesinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Griesinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Griesinger. The network helps show where Frank Griesinger may publish in the future.

Co-authorship network of co-authors of Frank Griesinger

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Griesinger. A scholar is included among the top collaborators of Frank Griesinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Griesinger. Frank Griesinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients 2025 ·Cancers ·(unknown), (unknown), (unknown), Stefanie Schmidt, (unknown), David Horst, Markus Möbs, Elena Ioana Braicu, Frank Griesinger, (unknown), Katharina Tiemann, Lukas C. Heukamp, Eva‐Maria Willing, Claudia Vollbrecht	1
2	Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial 2025 ·Lung Cancer ·Anne‐Marie C. Dingemans, Konstantinos Syrigos, Lorenzo Livi, (unknown), Sang‐We Kim, Yuanbin Chen, Enriqueta Felip, Frank Griesinger, Kadoaki Ohashi, Gérard Zalcman, Brett Hughes, Jens Benn Sørensen, Normand Blais, Carlos Gil Ferreira, Colin R. Lindsay, Rafał Dziadziuszko, Patrick J. Ward, (unknown), Yang Wang, Solange Peters	0
3	BIOLUMA: A phase II trial of nivolumab and ipilimumab in lung cancer—Results from the SCLC TMB^high cohort. 2024 ·Journal of Clinical Oncology ·Rieke Fischer, Julie George, (unknown), Hans Anton Schloesser, (unknown), Peter Brossart, Walburga Engel-Riedel, Frank Griesinger, Christian Grohé, (unknown), Kathrin Nachtkamp, Jens Panse, Martin Sebastian, Rainer Wiewrodt, Reinhard Büttner, Roman K. Thomas, Juergen Wolf	1
4	Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting. 2024 ·Journal of Clinical Oncology ·Rajiv Shah, Martin Reck, Christian Grohé, Daniel C. Christoph, (unknown), Felix Carl Saalfeld, Nikolaj Frost, Hans‐Georg Kopp, Martin Faehling, Frank Griesinger, (unknown), Petra Hoffknecht, Jonas Kuon, (unknown), (unknown), (unknown), Michael Thomas	1
5	Patient‐reported outcomes in advanced NSCLC before and during the COVID‐19 pandemic: Real‐world data from the German prospective CRISP Registry (AIO‐TRK‐0315) 2024 ·International Journal of Cancer ·Martin Sebastian, Wilfried Eberhardt, (unknown), Steffen Dörfel, (unknown), (unknown), Christoph Losem, Martina Jänicke, (unknown), Stefan Zacharias, (unknown), A. Hipper, (unknown), Annalen Bleckmann, (unknown), (unknown), Christian Grah, Annette Müller, Frank Griesinger, Michael Thomas, (unknown)	0
6	1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy 2023 ·Annals of Oncology ·(unknown), Jörg Möller, Sebastian Michels, Christian Grohé, Marcel Wiesweg, Christoph D. Schubart, (unknown), Frank Griesinger, Diego Kauffmann‐Guerrero, (unknown), Tobias R. Overbeck, (unknown), Gernot Rohde, Claas Wesseler, Ioannis Vathiotis, Rajwanth Veluswamy, (unknown), Sacha I. Rothschild, Petros Christopoulos, Martin Wermke	1
7	Early versus Delayed Tumor-Specific Therapy and Survival in Patients with Lung Cancer: A Retrospective Study 2023 ·Oncology Research and Treatment ·(unknown), Anna K.L. Reyners, Frank Griesinger, Burkhard Otremba, (unknown), Jörg Bäsecke	0
8	1380P Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial 2023 ·Annals of Oncology ·Santiago Viteri, Enriqueta Felip, Frank Griesinger, Marina Chiara Garassino, Hiroshi Sakai, Xiuning Le, Rémi Veillon, Egbert F. Smit, Jo Raskin, Michael Thomas, M-J. Ahn, Soetkin Vlassak, Rolf Bruns, Andreas Johne, Paul K. Paik	3
9	1329P FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC 2023 ·Annals of Oncology ·Lucia Nogová, Florian Malchers, Axel M. Hillmer, (unknown), (unknown), Sabine Merkelbach‐Bruse, Andreas H. Scheel, Janna Siemanowski, Matthias Scheffler, John Frank, (unknown), (unknown), Martin Wermke, Christian Grohé, Anna Kron, Niels Reinmuth, Frank Griesinger, Roman K. Thomas, Reinhard Büttner, Jennifer Moriatis Wolf	2
10	Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122) 2023 ·Clinical Lung Cancer ·Nikolaj Frost, Annalen Bleckmann, Frank Griesinger, Christian Grohé, Melanie Janning, Jens Kollmeier, Niels Reinmuth, Martin Sebastian, Michael J. Thomas, Martin Reck	0
11	Decision Conflicts in Clinical Care during COVID-19: A Multi-Perspective Inquiry 2022 ·Healthcare ·Jörg Haier, Johannes Beller, Kristina Adorjan, Stefan Bleich, Moritz de Greck, Frank Griesinger, Markus V. Heppt, René Hurlemann, Soeren Torge Mees, Alexandra Philipsen, Gernot Rohde, Georgia Schilling, (unknown), Stephanie E. Combs, Siegfried Geyer, (unknown)	6
12	Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts 2022 ·Cancers ·C. Chouaïd, Michael Thomas, D. Debieuvre, Isabelle Durand‐Zaleski, Stefan Zacharias, L. Bosquet, (unknown), (unknown), Alan Calleja, (unknown), (unknown), M. Daumont, John R. Penrod, Robert Carroll, (unknown), François-Emery Cotté, Clarisse Audigier-Valette, Frank Griesinger	3
13	Differences in Stakeholders’ Perception of the Impact of COVID-19 on Clinical Care and Decision-Making 2022 ·Cancers ·Jörg Haier, Johannes Beller, Kristina Adorjan, Stefan Bleich, Moritz de Greck, Frank Griesinger, Markus V. Heppt, René Hurlemann, Soeren Torge Mees, Alexandra Philipsen, Gernot Rohde, Georgia Schilling, Karolin Trautmann‐Grill, Stephanie E. Combs, Siegfried Geyer, (unknown)	3
14	Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer 2022 ·ESMO Open ·Jennifer Moriatis Wolf, Åslaug Helland, In‐Jae Oh, M.R. Migliorino, Rafał Dziadziuszko, Anna Wrona, Javier de Castro, Julien Mazières, Frank Griesinger, (unknown), Andrés F. Cardona, Thorsten Ruf, Kerstin Trunzer, Vlatka Smoljanović, Silvia Novello	25
15	Neoadjuvant and adjuvant end-points in health technology assessment in oncology 2021 ·European Journal of Cancer ·Nadia Harbeck, Andreas Schneeweiß, Peter Thuss‐Patience, Kurt Miller, Claus Garbe, Frank Griesinger, Wilfried Eberhardt, Jens Peter Klußmann, Barbara Wollenberg, Marc‐Oliver Grimm, Thomas Zander, Diana Lüftner	9
16	European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review 2021 ·Drugs - Real World Outcomes ·Riyaz Shah, Nicolas Girard, Saurabh Nagar, Frank Griesinger, (unknown), Keith L. Davis, Parisa Karimi, W. Sawyer, Ning Yu, Aliki Taylor, Josephine Feliciano	9
17	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer 2021 ·Lung Cancer ·Sanjay Popat, Odd Terje Brustugun, J. Cadranel, Enriqueta Felip, Marina Chiara Garassino, Frank Griesinger, Åslaug Helland, Maximilian J. Hochmair, M. Pérol, (unknown), (unknown), Silvia Novello	13
18	Transcription of AML1 in hematopoietic subfractions of normal adults 2002 ·Annals of Hematology ·(unknown), Michaela Feuring‐Buske, G. Brittinger, UW Schaefer, Wolfgang Hiddemann, Frank Griesinger	8
19	Leukaemia‐associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome 1999 ·British Journal of Haematology ·Frank Griesinger, (unknown), (unknown), Michael Falk, Anja Renziehausen, C. Troff, (unknown), Susanne Schnittger, Thomas Büchner, J. Ritter, Wolfgang Hiddemann, Bernhard Wörmann	49
20	Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome 1999 ·British Journal of Haematology ·Frank Griesinger, (unknown), (unknown), Michael Falk, Anja Renziehausen, C. Troff, (unknown), Susanne Schnittger, Thomas Büchner, J. Ritter, Wolfgang Hiddemann, Bernhard Wörmann	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact